小儿肺热咳喘口服液联合布地奈德雾化吸入对婴幼儿呼吸道合胞病毒肺炎Th17细胞的影响以及临床疗效分析

目的探讨小儿肺热咳喘口服液联合布地奈德雾化吸入对婴幼儿呼吸道合胞病毒肺炎(respiratory syncytial virus pneumonia,RSVP)辅助性T淋巴细胞(Th17)的影响,并分析其临床疗效。方法选取三亚市人民医院2017年2月-2018年12月收治的婴幼儿RSVP患者148例,将所有患儿使用数字表法随机分为对照组和观察组,每组74例。用流式细胞仪检测患儿外周血Th17细胞比例变化。用ELISA法检测IL-17表达。结果治疗前对照组和观察组患儿Th17细胞比例(12.11±2.12)%vs(12.03±2.24)%]和IL-17表达水平(33.65±5.36) ng/ml vs(32.14±5.47)ng/ml]差异无统计学意义;治疗后观察组同对照组比较,Th17细胞比例(6.75±1.43)%vs(10.73±2.56)%]和IL-17表达水平(16.48±3.14)ng/ml vs(25.71±4.46)ng/ml]显著降低(P<0.01)。观察组的患儿住院、体温恢复和啰音消失时间分别为(4.42±1.16)d、(2.38±0.52)d和(2.53±0.54)d,均显著短于对照组的(5.73±1.51)d、(3.52±0.64)d和(3.66±0.72)d(P<0.05)。观察组治疗有效率显著高于对照组(97.3%vs 82.4%,P<0.05)。对照组不良反应发生率为5.4%(4/74),观察组不良反应发生率为6.8%(5/74),差异无统计学意义。结论小儿肺热咳喘口服液联合布地奈德雾化吸入治疗婴幼儿RSVP,可以降低患儿外周血Th17细胞的比例,临床疗效显著,使用安全。

The effect of a widely used Chinese traditional medicinal oral liquid combined with budesonide on Th17 cells in infants with respiratory syncytial virus pneumonia and its clinical efficacy

Objective To evaluate the effect of Pediatric Fei-re-ke-chuan Oral Liquid(a kind of widely used Chinese traditional medicine in China) combined with budesonide on Th17 cells in infants with respiratory syncytial virus pneumonia(RSVP) and its clinical efficacy. Methods A total of 148 RSVP cases were enrolled in this study. Patients were divided into control group(n=74) and observation group(n=74). The proportion of Th17 cells in the peripheral blood of children was detected by flow cytometry.IL-17 expression was detected by ELISA analysis. Results Before treatment, there was no significant difference of Th17 cells(12.11±2.12)% vs(12.03±2.24)%] and IL-17(33.65±5.36) ng/ml vs(32.14±5.47)ng/ml]between the two groups(P>0.05).After treatment, Th17 cells(6.75±1.43)% vs(10.73±2.56)%] and IL-17(16.48±3.14)ng/ml vs(25.71±4.46)ng/ml]was lower in observation group than that in control group(P<0.01).The hospitalization time, temperature recovery time and rales disappearance time in observation group were(4.42±1.16)d,(2.38±0.52)d, and(2.53±0.54)d, respectively, which weresignificantly shorter than those of(5.73±1.51)d,(3.52±0.64)d,and(3.66±0.72)d in control group(P<0.05).The effective rate in observation group was 97.3%(72/74),which was significantly higher than that of 82.4%(61/74)in control group.The rate of adverse reaction was 5.4%(4/74)in control group and6.8%(5/74)in observation group.There was no significant difference between the two groups(P>0.05). Conclusions The Pediatric Fei-re-ke-chuan Oral Liquid combined with budesonide decreased Th17 cells in RSVP,with significantly clinical efficacy and safety.